Pfizer entered into a research collaboration deal with deCODE genetics to discover sequence variants associated with specific clinical phenotypes related to Systemic Lupus Erythematosis, the latter announced Wednesday. Under the agreement, the companies will work together over the next 18 months to analyse the genomes of patients to search for sequence variants that would be useful for understanding drug targets and discovering novel drug targets.
**published in "First Word"
No comments:
Post a Comment